Proteome Sciences has a long and successful track record in discovering, validating and implementing biomarkers in many different sample types and across a diverse range of indications. At the heart of our approach is the use of the very latest and most sensitive mass spectrometry instrumentation and techniques, coupled with our own proprietary Tandem Mass Tag® (TMT®) that allow tighter control on analytical variability and rapid development of mass spectrometry assays for biomarker validation. TMT® works like a car tracker system but only to monitor proteins and peptides.
TMT® protein labeling reagents and kits are commercially available exclusively from Thermo Scientific, and enable isobaric labeling of proteins extracted from cells, tissues and other biological samples for multiplexed quantitative measurement by mass spectrometry.
Prof. Steve Gygi, Department of Cell Biology, Harvard Medical School, discusses the impact the new Thermo Scientific™ Orbitrap Fusion™ Lumos™ MS technology will have on protein quantitation, cell biology research and ultimately the evolution of drug discovery and treatment, featuring Proteome Sciences proprietary Tandem Mass Tag® Technology-Video Link
Dr. Ian Pike, COO of Proteome Science, describes their work on developing new approaches to stratified medicine and bringing their mass spectrometry based proteomics approaches into the clinic. For example he describes SysQuant®, a hybrid proteomic/phosphoproteomic approach to stratifying mechanisms of disease in individual patients with pancreatic cancer, TMT Calibrator™ for low level identification of tissue derived biomarkers in body fluids and work on a CSF biomarker panel for Alzheimer’s disease. View the presentation here